Live Breaking News & Updates on Enanta Pharmaceuticals Company Profile Get Rating

Stay updated with breaking news from Enanta pharmaceuticals company profile get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

-$1.38 EPS Expected for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) This Quarter

Brokerages expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) to announce earnings per share (EPS) of ($1.38) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Enanta Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.75) and the highest is ($0.82). Enanta Pharmaceuticals posted earnings of ($1.19) per share […] ....

Bruce La Carter , Morgan Stanley , Zacks Investment Research , Enanta Pharmaceuticals Company Profile Get Rating , First Trust Advisors , Wells Fargo Company , Enanta Pharmaceuticals Inc , Enanta Pharmaceuticals , Abbott Laboratories , Royal Bank , Get Rating , Zacks Investment , Enanta Pharmaceutical , Director Bruce , Trust Advisors , Pharmaceuticals Company Profile , Nasdaq Enta ,

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Buy" by Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price […] ....

Bruce La Carter , Morgan Stanley , Zacks Investment Research , Enanta Pharmaceuticals Company Profile Get Rating , First Trust Advisors , Analyst Recommendations For Enanta Pharmaceuticals , Wells Fargo Company , Enanta Pharmaceuticals Inc , Enanta Pharmaceuticals , Abbott Laboratories , Royal Bank , Get Rating , Director Bruce , Trust Advisors , Pharmaceuticals Company Profile , Nasdaq Enta ,

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) have been given a consensus recommendation of “Hold” by the nine analysts that are presently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target […] ....

New York , United States , Bruce La Carter , Thomson Reuter , Northern Trust Corp , Geode Capital Management , Securities Exchange Commission , Zacks Investment Research , Enanta Pharmaceuticals Company Profile Get Rating , First Manhattan Co , Analyst Recommendations For Enanta Pharmaceuticals , Enanta Pharmaceuticals Inc , Enanta Pharmaceuticals , Abbott Laboratories , Get Rating , Investment Research , Exchange Commission , Director Bruce , Street Corp , Trust Corp , Capital Management , Pharmaceuticals Company Profile , Nasdaq Enta ,

Zacks: Analysts Anticipate Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Will Announce Earnings of -$1.43 Per Share

Brokerages expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) to announce earnings of ($1.43) per share for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Enanta Pharmaceuticals’ earnings. The highest EPS estimate is ($1.18) and the lowest is ($1.82). Enanta Pharmaceuticals reported earnings of ($1.09) per share in the same quarter […] ....

Bruce La Carter , Morgan Stanley , Securities Exchange Commission , Zacks Investment Research , Enanta Pharmaceuticals Company Profile Get Rating , First Trust Advisors , Enanta Pharmaceuticals Inc , Squarepoint Ops , Enanta Pharmaceuticals , Royal Bank , Get Rating , Enanta Pharmaceutical , Investment Research , Exchange Commission , Director Bruce , Trust Advisors , Pharmaceuticals Company Profile , Nasdaq Enta ,